Industry News

Drug and Alcohol Testing

November 05, 2018

At DISA’s ‘Day with DISA’ drug testing conference and networking event on October 29th, DISA helped educate employers on valuable drug testing insights that will help them further protect their company. Colin Woods, DISA’s Vice President of Sales and Marketing presented on the History of Drug Testing and our 2019 Owner Survey to bring awareness to the powerful impact drug testing has in the workplace.

Drug and Alcohol Testing

October 31, 2018

Effective January 1, 2019, the Federal Transit Administration (FTA) is increasing its annual random drug testing rate from 25% to 50%. This is the first increase in random testing rates since 2007 and a direct result of positivity rates increasing to 1.06% in 2017.

Acquisitions

October 23, 2018

DISA Global Solutions continues to expand its geographic reach, expertise, and depth of services through strategic acquisition. Effective October 1, 2018, DISA has acquired Occupational Drug Testing, LLC (ODT). This transaction significantly enhances DISA’s scope of mobile capabilities as well as aligning a complementary service offering to the DISA portfolio.

Background Check

October 15, 2018

This is the first in our new series of blog posts aimed at helping the HR Professional navigate the ever-changing employee screening industry. With new laws being implemented every day, staying up to date on industry best practices is more crucial than ever! Sign up for our newsletter to receive each of these HR 101 posts as they’re released.

Transportation Compliance

October 08, 2018

The Federal Motor Carrier Safety Administration revised federal regulations for individuals with a stable insulin regimen and properly controlled insulin-treated diabetes mellitus (ITDM) to be qualified to operate commercial motor vehicles (CMVs) and will go into effect on November 19, 2018.

Drug and Alcohol Testing

September 25, 2018

In late June 2018, the Food and Drug Administration (FDA) approved Epidiolex for sale in the U.S. It is the first prescription drug derived from the marijuana plant. The drug is designed to treat seizures for two rare forms of epilepsy: Dravet Syndrome and Lennox-Gastaut Syndrome. “Fast-track” designation was given to the drug during its approval process because it was the first FDA approval of a drug for the treatment of patients with Dravet Syndrome.1 “Orphan drug” designation (special status given to a drug that treats a rare condition or disease) was also given to the drug for use as a treatment for both Dravet Syndrome and Lennox-Gastaut Syndrome.

Company Announcements

September 18, 2018

In a 2018 Drug Testing Industry and Brand Name Recognition Survey, DISA Global Solutions was ranked first among drug testing third-party administrators (TPA). This marks the second year in a row DISA has been voted the most recognized brand.  In addition, we are pleased to report that University Services (a DISA Global Solutions company) was voted #1 among Medical Review Officers (MRO’s) in brand recognition for the third consecutive year.